Recognizing CADASIL: a Secondary Cause of Migraine with Aura
- 558 Downloads
Purpose of Review
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an important disease to consider in the differential diagnosis of migraine with aura. This review examines current literature regarding migraine in CADASIL, as well as diagnostic and treatment modalities.
Recent studies have shown that smoking is a modifiable risk factor for progression of CADASIL (Chabriat et al. in Stroke 47:4–11, 2015). Specific imaging changes and findings on clinical exam can predict disease progression. However, migraine symptoms often precede MRI changes (Guey et al. in Cephalalgia 36:1038–47, 2015). A recent paper on migraine treatment in CADASIL reevaluates the prevailing belief that vasoconstrictive abortive medications are contraindicated in these patients (Tan and Markus in PLoS ONE 11:e0157613, 2016).
CADASIL is an autosomal dominantly inherited vasculopathy causing ischemic pathology in younger individuals due to a mutation in the NOTCH3 gene. The mutation results in impaired arterial contractility due to accumulation of granular osmiophilic extracellular material (GOM) in vascular smooth muscle cells (VSMCs). Clinical manifestations include migraine with and without aura, cognitive decline, ischemic events, and mood disorders. The presenting symptom is often migraine with aura. Characteristic MRI changes are often present. Genetic screening is available to confirm NOTCH3 mutation and pathognomic changes are often seen in skin biopsy. Treatment of migraine is similar to the general population, but with some notable and specific differences. Further studies in CADASIL, other small vessel arteriopathies, and migraine may help us understand more about the pathophysiology of these conditions and help with treatment development.
KeywordsMigraine Aura CADASIL Arteriopathy Cerebral infarction Leukoencephalopathy NOTCH3
Compliance with Ethical Standards
Conflict of Interest
Dr. John Glenn Burkett and Dr. Carrie Dougherty each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.• Guey S, Mawet J, Herve D, Duering M, Godin O, Jouvent E, et al. Prevalence and characteristics of migraine in CADASIL. Cephalalgia. 2015;36:1038–47. Prospective cohort of 378 CADASIL patients evaluating migraine symptoms and possible correlates with symptoms, severity and MRI findings.CrossRefGoogle Scholar
- 12.•• Tan R, Markus H. CADASIL: migraine, encephalopathy, stroke and their inter-relationships. PLoS ONE. 2016;11:e0157613. Recently completed prospective study with 300 symptomatic CADASIL patients examining migraine patterns, treatment responses and associations between migraine, stroke and encephalopathy. First article to document use of vasoconstrictive treatment with triptans and ergots in CADASIL patients.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Liem M, Lesnik Oberstein S, Haan J, van der Neut I, van den Boom R, Ferrari M, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: progression of MR abnormalities in prospective 7-year Follow-up Study. Radiology. 2008;249:964–71.CrossRefPubMedGoogle Scholar
- 22.•• Chabriat H, Hervé D, Duering M, et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2015;47:4–11. Prospective cohort study of 290 CADASIL patients evaluating for demographic, clinical, and MRI predictors of stroke, dementia, clinical worsening and death. Underlines importance of imaging and exam in predicting disease progression and showed that smoking is a modifiable risk factor for progression.CrossRefPubMedGoogle Scholar
- 24.• Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299–302. Retrospective study looking at 7 patients treated with acetazolamide for migraine prophylaxis and their responses.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.• Ferrari M, Klever R, Terwindt G, Ayata C, van den Maagdenberg A. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14:65–80. Review article summarizing recent findings in mouse models and possible connections in humans in regards to migraine and aura pathophysiology.CrossRefPubMedGoogle Scholar